Effects of the TRPV1 antagonist ABT-102 on body temperature in healthy volunteers: pharmacokinetic/ pharmacodynamic analysis of three phase 1 trials

Randomised clinical trial: the efficacy of a transient receptor potential vanilloid 1 antagonist AZD1386 in human oesophageal pain

(2011) A. L. Krarup et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

An investigation of the safety and pharmacokinetics of the novel TRPV1 antagonist XEN-D0501 in healthy subjects

(2011) Patrick Round et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Pharmacokinetics of the TRPV1 Antagonist ABT-102 in Healthy Human Volunteers: Population Analysis of Data From 3 Phase 1 Trials

(2011) Ahmed A. Othman et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Transient receptor potential channels as therapeutic targets

(2011) Magdalene M. Moran et al.   NATURE REVIEWS DRUG DISCOVERY

Oral and cutaneous thermosensory profile of selective TRPV1 inhibition by ABT-102 in a randomized healthy volunteer trial

(2011) Michael C. Rowbotham et al.   PAIN

Repeated dosing of ABT-102, a potent and selective TRPV1 antagonist, enhances TRPV1-mediated analgesic activity in rodents, but attenuates antagonist-induced hyperthermia

(2009) Prisca Honore et al.   PAIN

Clinical development of TRPV1 antagonists: targeting a pivotal point in the pain pathway

(2008) Martin J. Gunthorpe et al.   DRUG DISCOVERY TODAY

Identification of (R)-1-(5-tert-Butyl-2,3-dihydro-1H-inden-1-yl)-3-(1H-indazol-4-yl)urea (ABT-102) as a Potent TRPV1 Antagonist for Pain Management

(2008) Arthur Gomtsyan et al.   JOURNAL OF MEDICINAL CHEMISTRY

(R)-(5-tert-Butyl-2,3-dihydro-1H-inden-1-yl)-3-(1H-indazol-4-yl)-urea (ABT-102) Blocks Polymodal Activation of Transient Receptor Potential Vanilloid 1 Receptors in Vitro and Heat-Evoked Firing of Spinal Dorsal Horn Neurons in Vivo

(2008) C. S. Surowy et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Pharmacological blockade of the vanilloid receptor TRPV1 elicits marked hyperthermia in humans

(2008) Narender R. Gavva et al.   PAIN